Joint ACNFP and COT cannabidiol (CBD) subgroup phase 1 summary report
Summary report from the joint ACNFP and COT subgroup on phase 1 of their work on cannabidiol (CBD).
Documents
Details
The subgroup concluded the first phase of their work after 14 meetings. The subgroup concluded the following outputs had been delivered.
A position paper – establishing a science based provisional ADI for Group A CBD ingredients ≥98% pure at 10 mg CBD/day for a healthy 70 kg adult, which has formed the basis of updated FSA Consumer Advice in October 2023. Important caveats remain about data gaps for reproductive toxicity and immunotoxicity leading to advisory statements about the protection of children, pregnant women, those trying to conceive a baby and immunocompromised individuals. No general advice can be identified for CBD novel foods with less than 98% purity as the impact of the toxicology from other components present will need detailed consideration.
A position paper – deriving a safe upper limit of 1 µg/kg bw/day for the contaminant THC in CBD ingredients, based on the scientific evidence, which can be used in setting specifications and in novel foods safety assessment to ensure the safety of consumers from this illegal drug.
Clarity that general advice cannot be established for CBD novel foods with less than 98% purity.
An FSA Evidence base to underpin the justification for the Group A provisional ADI, with a useful graphic to explain how the ADI protects against all potential health effects of CBD.
Outputs and statements from the subgroup were subject to review and agreement by both the COT and ACNFP before publication.